Navigation Links
Effective Treatment Option For Macular Degeneration

The wet form of macular degeneration represents about 10 percent of the overall disease prevalence. Age-related macular degeneration is the leading cause of irreversible, severe vision loss in people 50 years of age and older. // Two new studies show a therapy known as pegaptanib (Macugen) is an effective treatment for age-related, "wet" macular degeneration.

The trials were conducted at 117 centers in the United States, Canada, Europe, Israel, Australia and South America and a total of 1,208 patients were involved in the study. The participants received either 0.3 milligrams of pegaptanib, 1.0 milligrams of pegaptanib, 3.0 milligrams of pegaptanib, or a placebo.

Researchers observed a significant difference in patients who received the pegaptanib as early as six weeks after the treatment was given. The maximum benefit was observed after 54 weeks of treatment. Pegaptanib also reduced the chance of the loss of 15 letters or more of visual acuity, which is considered a moderate loss. It also reduced the chance of the loss of 30 letters or more (six lines on the eye chart), which is considered a severe loss.

Thus researchers say treatment with pegaptanib reduced the risk of progression to legal blindness in the study, promoted stability of vision, and in a small percentage of patients, resulted in more visual improvement at week 54 than among those receiving sham injections.
'"/>




Page: 1

Related medicine news :

1. New Way to "See" Genes, Evaluate Effectiveness of Gene Therapies Discovered
2. Inhaled Steroids Safe & Effective for Children with Asthma
3. ZD1839 Proves Effective - A Breakthrough in fighting Lung Cancer
4. Fluoride Found Effective in Osteoporosis
5. Aspirin and Warfarin Are Equally Effective for Stroke Prevention
6. Implantable Contact Lens Found Safe and Effective
7. Effective And Economical Agent For Anthrax
8. Stem Cell Transplants May Be Effective For MS Patients
9. Effective therapy for Huntingtons disease
10. Chemotherapy Effective for Bladder Cancer
11. Drug Effective for Vascular Dementia

Post Your Comments:
(Date:11/22/2009)...-USNewswire/ -- Congressman Chaka Fattah (D-PA) is...s Senate,s vote tonight to proceed to debate on Af...Arlen Specter and Bob Casey deserve the thanks of ...stand-up, critical votes in the Senate tonight adv...h Care Reform legislation to full debate. The Pres...
(Date:11/21/2009).../ -- Milvia Lopez, by her attorney MICHAEL STEWART...n Supreme Court, New York County, bearing Index # ...Lopez underwent a routine transesophageal echocard...s used an HIV infected scope exposing her to HIV. ...fter being discharged from the procedure and arriv...
(Date:11/21/2009)...l credentialing software company IntelliSoft Group...p with Amerinet, Inc., the leading healthcare G.P....sform quality care within the healthcare market. ...9 -- ISG Group, LLC, doing business as IntelliSoft...t Inc., a leading national healthcare group purcha...
(Date:11/21/2009)...l Group merges their practice with that of E. Stev... (PRWEB) November 21, 2009 -- The New H... Gibson, Dr. Dean Cloutier, Dr. John Plachtyna and...g practice with that of esteemed colleague Dr. E. ...nted to retire from dentistry in order to concentr...
(Date:11/20/2009)...ire-USNewswire/ -- The American Academy of Actuar...form legislation released this week to contain str...dual coverage mandate. The actuaries said that an ...verse selection stemming from more restrictive iss..."The individual mandate language should be strengt...
Breaking Medicine News(10 mins):Health News:Patient Files Suit Against St. Vincent's Hospital in New York City as a Result of the Alleged Use by the Hospital of an HIV Infected Device During a Routine Procedure 2Health News:IntelliSoft Group and Amerinet Inc. Form Partnership to Transform Healthcare Delivery of Quality Patient Safety and Care 2Health News:New Haven Dental Group Expands Their Vision 2Health News:Actuaries to Senate: Strengthen Individual Mandate 2
...ene Therapeutics Research Institute at Cedars-Sina...t it is possible to sustain therapeutic gene expre...ar, even in the presence of an anti-viral immune r...vel gutted adenoviral vector called HC-Adv, is com...
...rm outcomes, researchers say , THURSDAY, Oct. 25 (...rial natriuretic peptide (ANP) can lessen cardiac ...omes, a new study finds. , According to a Japanese...usion injuries," caused when blood rushes back to ...
...compare more than 500 health pla...26 U.S.News & World Report and the,National Commi...he third,edition of America,s Best Health Plans, a...families face health plan,selection options, the r...
...k Engineer and Information, Technology Magazines ..., ABBOTT PARK, Ill., Oct. 26 Abbott (NYSE: ABT ... diversity in two publications.,Abbott was named a...rsity in the magazine. In addition, Abbott was,nam...
...lth Plans, Lists for Third ...e third consecutive year,HealthPlus of Michigan,s ...,plans have been recognized by U.S. News & World R...are and Medicaid in the,national news magazine,s U...
...and,House Democratic leaders held a news conferenc...n the revised bipartisan SCHIP bill, which passed ...pening remarks:, "Today we took another step forw...ation where on the motion to recommit,the Republic...
Other Medicine News:Health News:U.S.News & World Report, NCQA Release Annual Rankings for 'America's Best Health Plans' 2Health News:U.S.News & World Report, NCQA Release Annual Rankings for 'America's Best Health Plans' 3Health News:Abbott Again Honored as a Leader in Diversity 2Health News:Abbott Again Honored as a Leader in Diversity 3
(Date:11/20/2009)...wswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CY... Chief Executive Officer, and Greg Browne, Chief F...Piper Jaffray Health Care Conference in New York o...e conference session and webcast will be audio onl...affray will host a webcast of the presentation liv...
(Date:11/20/2009).... 20 BD (Becton, Dickins... completion of its acquisition of HandyLab, Inc., ... and manufactures molecular diagnostic assays and ...ndyLab announced an exclusive agreement for BD to ...HandyLab Jaguar(TM) platform, the first fully inte...
(Date:11/20/2009)...0 Soligenix, Inc. (OTC B...ormerly known as DOR BioPharma, Inc., a late-stage...s formed a consortium to develop thermostable tech...ng vaccines. Soligenix received a $9.4 million gra...ctious Diseases (NIAID), a division of the Nationa...
Breaking Medicine Technology:Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference 2BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6New evidence that dark chocolate helps ease emotional stress 10691 1Exploration by explosion 3A Studying the inner realm of living cells 10689 1Mental Health America Partners With Prescription Audio To Donate 245M in PTSD Treatment Products to Veterans Active Duty Families Providers 61148 1Mental Health America Partners With Prescription Audio To Donate 245M in PTSD Treatment Products to Veterans Active Duty Families Providers 61148 2Mental Health America Partners With Prescription Audio To Donate 245M in PTSD Treatment Products to Veterans Active Duty Families Providers 61148 3
... EVRY, France, April 04, 2007 /PRNewswire/ -- Nov...l company specialized in,ophthalmology, announces ... study of Vekacia(R) in children suffering from Ve...sease, it was shown,that both symptoms and signs o...). Furthermore, the tolerability to Vekacia(R),was...
... Data to be Presented at the XXI Congress of the I..., SOUTH SAN FRANCISCO, Calif., April 04, 2007 /PRN...nounced that it has received,positive results from...hibitor, PRT054021, for the prevention of venous,t...ent (TKR),surgery. Based on these results, Portola...
Other Medicine Technology:Novagali Pharma Announces Positive Vekacia Clinical Results From,Pivotal Phase III Trial in Vernal Keratoconjunctivitis 2Portola Pharmaceuticals Announces Positive Phase II Results for,PRT054021 for Prevention of Venous Thromboembolism Following Total,Knee Replacement Surgery 2Portola Pharmaceuticals Announces Positive Phase II Results for,PRT054021 for Prevention of Venous Thromboembolism Following Total,Knee Replacement Surgery 3
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
Medicine Products: